Condition (MeSH)
Polypoidal Choroidal Vasculopathy
ClinicalTrials.gov lists 50 trials for Polypoidal Choroidal Vasculopathy or a narrower condition beneath it. Singapore National Eye Centre has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
50 of the 50 trials are tagged with Polypoidal Choroidal Vasculopathy itself; the rest are tagged with a narrower condition beneath it.
When did Polypoidal Choroidal Vasculopathy trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 4 |
| 2018 | 3 |
| 2017 | 5 |
| 2016 | 2 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Polypoidal Choroidal Vasculopathy trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 5 |
| Phase 2 | 3 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Phase 4 | 14 |
| Not applicable | 8 |
| Observational | 13 |
How many Polypoidal Choroidal Vasculopathy trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 25 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Polypoidal Choroidal Vasculopathy trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Singapore National Eye Centre | 4 |
| Fondation Ophtalmologique Adolphe de Rothschild | 2 |
| Novartis Pharmaceuticals | 2 |
| Ophthotech Corporation | 2 |
Which drugs are being tested for Polypoidal Choroidal Vasculopathy? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Conbercept | 3 |
| Zimura | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| ranibizumab PRN | 8 |
| 2.0 aflibercept | 7 |
| Indocyanine green angiography (intraveonus indocyanine green dye) | 2 |
| Verteporfin PDT | 2 |
| Intravitreal Aflibercept | 2 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Polypoidal Choroidal Vasculopathy trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 6 | 2 |
| Vitreous haemorrhage (Study eye) | 4 | 1 |
| Fall | 3 | 2 |
| Acute myocardial infarction | 2 | 1 |
| Anaemia | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Polypoidal Choroidal Vasculopathy? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Aflibercept With vs Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. | JAMA ophthalmology | 2025 | No |
| Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis. | Japanese journal of ophthalmology | 2025 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.